50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Myeloproliferative Disorders--Biology and Clinical Studies Poster I

Saturday, December 6, 2008: 5:30 PM-7:30 PM

Hall A (Moscone Center)

Efficacy and Safety of Primary Antithrombotic Prophylaxis with Ticlopidine and with Aspirin In Patients with Essential Thrombocythemia and Polycythemia Vera. Results from a Cohort Study

Marco Ruggeri¹^*, Alberto Tosetto²^*, Irene Bolgan¹^* and Francesco Rodeghiero¹

¹Hematology, San Bortolo Hospital, Vicenza, Italy
²Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy

1744

Minimal Residual Disease and Normalization of the Bone Marrow after Long-Term Treatment with Alpha-Interferon2b in Polycythemia Vera. A Report on Seven Patients in Sustained Complete Hematological Remission with Major Molecular Responses

Thomas Stauffer Larsen¹^*, Michael Boe Møller²^*, Karin de Stricker²^*, Peter Nørgaard³^*, Jan Samuelsson⁴^*, Claus Marcher¹^*, Ole Weis Bjerrum⁵^*, Morten T Andersen⁵^* and Hans Carl Hasselbalch⁶^*

¹Department of Hematology X, Odense University Hospital, Odense, Denmark
²Department of Pathology, Odense University Hospital, Odense, Denmark
³Department of Pathology, Herlev Hospital, Herlev, Denmark
⁴Department of Internal Medicine, Section of Hematology, Stockholm South Hospital, Stockholm, Sweden
⁵Department of Hematology L, Rigshospitalet, Copenhagen, Denmark
⁶Department of Hematology L, Herlev Hospital, Herlev, Denmark

1745

Alessandra Carobbio¹^*, Guido Finazzi²^*, Elisabetta Antonioli³^*, Paola Guglielmelli⁴^*, Alessandro M. Vannucchi⁵, Federica Delaini¹^*, Alessandro Rambaldi⁶ and Tiziano Barbui¹^*

¹USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
²Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
³Hematology, Università degli Studi di Firenze, Firenze, Italy
⁴Hematology, UniversitÃƒÂƒÃ‚Â degli Studi di Firenze, Firenze, Italy
⁵Hematology, UniversitÃ degli Studi di Firenze, Firenze, Italy
⁶Clinical Hematology Division, Hospital de Sant Pau, Barcelona, Spain

1746

Long-Term Outcome in Polycythemia Vera (PV): Final Analysis of a Randomized Trial Comparing Hydroxyurea (HU) to Pipobroman (Pi)

Jean-Jacques Kiladjian¹^*, Sylvie Chevret²^*, Christine Dosquet³^*, Pierre Fenaux¹, Christine Chomienne³ and Jean-Didier Rain³^*

¹Hématologie Clinique, Assistance Publique - Hôpitaux de Paris, Hôpital Avicenne; Paris 13 University, Bobigny, France
²Dbim, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France
³Unité de Biologie Cellulaire, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France

1747

Risk Stratification for Survival and Clonal Progression in Essential Thrombocythemia (ET): Result of a Prospective Study of 108 Patients with Very Long Term Follow up

Jean-Jacques Kiladjian¹^*, Sylvie Chevret²^*, Jean-François Abgrall³^*, Yasmine Chait⁴^* and Jean Briere⁵

¹Hématologie Clinique, Assistance Publique - Hôpitaux de Paris, Hôpital Avicenne; Paris 13 University, Bobigny, France
²Dbim, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France
³Laboratoire d'Hématologie, CHU de Brest, Brest, France
⁴Hématologie Clinique, CH de Montfermeil, Montfermeil, France
⁵Hématologie Clinique, Assistance Publique - Hôpitaux de Paris, Hôpital Beaujon, Clichy, France

1748

Improved Survival in Red Blood Cell Transfusion Dependent Patients with Primary Myelofibrosis (PMF) Receiving Iron Chelation Therapy

Heather Leitch, MD, PhD¹, Hatoon Ezzat, MBBS²^*, Meaghan D Rollins, BHK³^*, Trisha A Goodman, BHK³^*, Chantal S Leger, MD¹^*, Dominic HC Wong, BSc³^*, Khaled M Ramadan, MB¹, Lynda M Foltz, MD¹^* and Linda M Vickars, MD¹^*

¹Hematology, St. Paul's Hospital, Vancouver, BC, Canada
²Hematology, UBC, Vancouver, BC, Canada
³Medicine, UBC, Vancouver, BC, Canada

1749

High Frequency of the JAK2 V617F Mutation in Patients with Trisomy of Chromosome 9

Hossein Mossafa III, PHD¹^*, Hamid Belaouni II, MD²^*, Veronique Saada, PHD³^*, Christine Fourcade Sr., MD²^*, J.Pierre Hurst Sr., MD⁴^* and Driss Chaoui III, MD²^*

¹Departement Genetics, Cerba-Pasteur, Cergy-Pontoise, France
²Heamatology, CH Argenteuil, Argenteuil, France
³Departement Genetics, Pasteur-cerba, Cergy-Pontoise, France
⁴Heamatology, CH Le Havre, Montivilliers, France

1750

Limited Efficacy of Hydroxyurea in Lowering of the JAK2 V617F Allele Burden

Thomas Stauffer Larsen¹^*, Niels Pallisgaard²^*, Karin de Stricker³^*, Michael Boe Møller⁴^* and Hans Carl Hasselbalch⁵

¹Department of Hematology X, Odense University Hospital, Odense, Denmark
²Hematology, Vejle Sygehus, Vejle
³Department of Pathology, Odense University Hospital, Odense, Denmark
⁴Odense University Hospital
⁵Department of Hematology L, Herlev Hospital,, Herlev Hospital, Herlev 2, Denmark

1751

Leukocytosis at Diagnosis and the Risk of Subsequent Thrombosis in Low-Risk Essential Thrombocythemia and Polycythemia Vera

Naseema Gangat, MD¹, Alexandra Wolanskyj, MD², Susan Schwager³^*, Curtis A. Hanson, MD³^* and Ayalew Tefferi, MD⁴

¹Hematology, Mayo Clinic, Rochester, MN
²Mayo Clinic Mayo Building West 10, Rochester, MN
³Mayo Clinic, Rochester, MN
⁴Medicine, Division of Hematology, Mayo Clinic Graduate School of Medicine, Rochester, MN

1752

Predictors of Pregnancy Outcome in Essential Thrombocythemia: A Single Institution Study of 63 Pregnancies

Naseema Gangat, MD¹, Alexandra Wolanskyj, MD², Susan Schwager³^* and Ayalew Tefferi, MD⁴

1753

Lenalidomide and Prednisone for Primary and Post Polycythemia Vera/ Essential Thrombocythemia Myelofibrosis (MF): An Eastern Cooperative Oncology Group (ECOG) Phase II Trial

Ruben A. Mesa, MD, FACP¹, Xiaopan Yao²^*, Larry D. Cripe, MD³, Chin Yang Li, MD¹^*, Ayalew Tefferi, MD⁴ and Martin S. Tallman, MD⁵

¹Mayo Clinic, Rochester, MN
²Harvard
³Indiana University Simon Cancer Center, Indianapolis, IN
⁴Medicine, Division of Hematology, Mayo Clinic Graduate School of Medicine, Rochester, MN
⁵Northwestern University Feinberg School of Medicine, Chicago, IL

1754

Assessment and Monitoring of Constitutional Symptoms in Patients with Myelofibrosis: A Proposed New Instrument the Myelofibrosis Symptom Assessment Form (MFSAF)

Ruben A. Mesa, MD, FACP¹, Susan Schwager¹^*, Deepti Radia, MD²^*, Andrea Cheville, MD³^*, Kebede Hussein, MD⁴, Joyce Niblack, JD⁵^*, Animesh D. Pardanani, MBBS, PhD¹, David P. Steensma, MD, FACP⁶, Mark R. Litzow, MD¹, Candido E. Rivera, MD⁷, John Camoriano, MD⁸, Srdan Verstovsek⁹, Jeffrey Sloan, PhD¹⁰^*, Claire Harrison, MD²^* and Ayalew Tefferi, MD¹¹

¹Mayo Clinic, Rochester, MN
²St. Thomas's, London, United Kingdom
³Physical Medicine, Mayo Clinic, Rochester, MN
⁴Internal Medicine, Mayo Clinic, Rochester, MN
⁵CMPD Education Foundation
⁶Medicine, Division of Hematology, Mayo Clinic Graduate School of medicine, Rochester, MN
⁷Mayo Clinic, Jacksonville, FL
⁸Mayo Clinic Scottsdale, Scottsdale, AZ
⁹M.D. Anderson Cancer Center, Houston, TX
¹⁰Cancer Center Biostatistics, Mayo Clinic, Rochester, MN
¹¹Medicine, Division of Hematology, Mayo Clinic Graduate School of Medicine, Rochester, MN

1755

Imatinib at Weekly Dosage May Induce and Maintain Haematologic and Molecular Remission in Chronic Eosinophilic Leukemia Harbouring FIP1L1-PDGFRA Fusion Gene- An Extended Follow-up Study

Grzegorz Helbig¹^*, Malgorzata Calbecka²^*, Justyna Gajkowska²^*, Andrzej Moskwa³^*, Alina Urbanowicz⁴^*, Alina Swiderska⁴^*, Jacek Najda¹^* and Slawomira Krzemien¹^*

¹Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
²Haematology, Provincial Hospital, Torun, Poland
³Haematology, Provincial Hospital, Gorzow, Poland
⁴Haematology, Provincial Hospital

1756

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) as a Curative Therapy in Primary and Secondary Myelofibrosis (MF): A 14-Year Period Oligocentric French Experience

Severine Lissandre¹^*, Jacques-Olivier Bay²^*, Jean-Yves Cahn³^*, Victoria Cacheux²^*, Aurélie Cabrespine²^*, Denis Guyotat⁴^*, Bruno Cassinat⁵^*, Regis Peffault de Latour¹^*, Gerard Socie¹ and Marie Robin¹^*

¹Service d'Hematologie - Transplantation, CHU Saint - Louis - APHP, Paris, France
²Service de Therapie Cellulaire et d'hematologie clinique adulte, CHU Hôtel-Dieu, Clermont-Ferrand, France
³Hématologie clinique, CHU Michallon, Grenoble, France
⁴Hématologie clinique, Institut de Cancérologie de la Loire, Saint Etienne, France
⁵Unité de biologie cellulaire, CHU Saint - Louis, Paris, France

1757

Revisiting Mastocytosis in Adults: A Mayo Clinic Case Series of 342 Patients Including Information on KITD816V and JAK2V617F

Ken-Hong Lim¹^*, Ayalew Tefferi, MD², Terra L Lasho, MT(ASCP)³^*, Christy Finke, BS¹^*, Chin Yang Li, MD⁴^* and Animesh D. Pardanani, MBBS, PhD⁴

¹Hematology, Mayo Clinic, Rochester, MN
²Medicine, Division of Hematology, Mayo Clinic Graduate School of Medicine, Rochester, MN
³Hematology Research, Mayo Clinic, Rochester, MN
⁴Mayo Clinic, Rochester, MN

1758

Recombinant Interferon Alpha (rIFNα) May Retard Progression of Early Primary Myelofibrosis (PM) by Reducing Splenomegaly and by Changing Marrow Morphology

Benjamin Levy^*, Katherine Vandris^*, Fernando Adriano^*, Joshua Goldman^* and Richard T. Silver

Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY

1759

Cytoreductive Therapy in Systemic Mastocytosis: Outcome Analysis and Response Prediction in 134 Consecutive Patients

Ken-Hong Lim¹^*, Animesh D. Pardanani, MBBS, PhD¹, Joseph H Butterfield, MD²^*, Chin Yang Li, MD³^* and Ayalew Tefferi, MD¹

¹Hematology, Mayo Clinic, Rochester, MN
²Division of Allergy, Mayo Clinic, Rochester, MN
³Mayo Clinic, Rochester, MN

1760

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF)

Ruben A. Mesa, MD, FACP¹, Srdan Verstovsek², Hagop M. Kantarjian, MD², Animesh D. Pardanani, MBBS, PhD¹, Steven Friedman, MD³^*, Robert Newton⁴^*, Susan Erickson-Viitanen⁴^*, Deborah Hunter⁴^*, John Redman, MD⁴^*, Swamy Yeleswaram⁴^*, Edward Bradley, MD⁴^* and Ayalew Tefferi, MD⁵

¹Mayo Clinic, Rochester, MN
²M.D. Anderson Cancer Center, Houston, TX
³Incyte Corporation, Wilmington, DE
⁴Incyte Co., Wilmington, DE
⁵Medicine, Division of Hematology, Mayo Clinic Graduate School of Medicine, Rochester, MN

1761

Gender Is a Phenotypic Modifier in the JAK2 V617F-Positive MPD

Brady L. Stein, MD, Donna Williams, PhD^*, Ophelia Rogers^*, Mary Ann Isaacs^*, Naveen Pemmaraju, MD^* and Alison R Moliterno, MD

Medicine, Johns Hopkins University School of Medicince, Baltimore, MD

1762

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ET-MF)

Srdan Verstovsek¹, Hagop M. Kantarjian, MD¹, Animesh D. Pardanani, MBBS, PhD², Deborah Thomas, MD¹^*, Jorge Cortes, MD¹, Ruben A. Mesa, MD, FACP², William J. Hogan, MBChB², John R. Redman, MD³, Sue Erickson-Viitanen³^*, Richard Levy, MD³^*, Kris Vaddi, PhD, DVM³^*, Edward Bradley, MD³^*, Jordan Fridman, PhD³^* and Ayalew Tefferi, MD²^*

¹M.D. Anderson Cancer Center, Houston, TX
²Mayo Clinic, Rochester, MN
³Incyte Corporation, Wilmington, DE

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

634.P1.73 Myeloproliferative Disorders--Biology and Clinical Studies Poster I